Trimethobenzamide hydrochloride capsule
Spl unclassified section
Chemically, trimethobenzamide HCl is N-[ p-[2-(dimethylamino)ethoxy]benzyl]-3,4,5-trimethoxybenzamide monohydrochloride. It has a molecular weight of 424.93 and the following structural formula:
Each capsule for oral use contains trimethobenzamide hydrochloride equivalent to 300 mg.
Inactive Ingredients: FDA/E172 Red Iron Oxide, gelatin, magnesium stearate, microcrystalline cellulose, sodium starch glycolate and titanium dioxide. The imprinting ink contains D&C Yellow #10 Lake, FD&C Blue #1, FD&C Blue #2, FD&C Red #40, Iron Oxide Black, propylene glycol and shellac glaze.
Mechanism of action
The mechanism of action of trimethobenzamide hydrochloride capsules, USP as determined in animals is obscure, but may involve the chemoreceptor trigger zone (CTZ), an area in the medulla oblongata through which emetic impulses are conveyed to the vomiting center; direct impulses to the vomiting center apparently are not similarly inhibited. In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against emesis induced by intragastric copper sulfate.
The pharmacokinetics of trimethobenzamide have been studied in healthy adult subjects. Following administration of 200 mg (100 mg/mL) trimethobenzamide hydrochloride I.M. injection, the time to reach maximum plasma concentration (T max) was about half an hour, about 15 minutes longer for trimethobenzamide hydrochloride 300 mg oral capsule than an I.M. injection. A single dose of trimethobenzamide hydrochloride 300 mg oral capsule provided a plasma concentration profile of trimethobenzamide similar to trimethobenzamide hydrochloride 200 mg I.M. The relative bioavailability of the capsule formulation compared to the solution is 100%. The mean elimination half-life of trimethobenzamide is 7 to 9 hours. Between 30 50% of a single dose in humans is excreted unchanged in the urine within 4872 hours. The major pathway of trimethobenzamide metabolism is through oxidation resulting in the formation of trimethobenzamide N-oxide metabolite. The pharmacologic activity of this major metabolite has not been evaluated.
The clearance of trimethobenzamide is not known in patients with renal impairment. However, it may be advisable to consider reduction in the dosing of trimethobenzamide in elderly patients with renal impairment considering that a substantial amount of excretion and elimination of trimethobenzamide occurs via the kidney and that elderly patients may have various degrees of renal impairment. (See PRECAUTIONS: General and DOSAGE AND ADMINISTRATION ).
Systemic exposure to trimethobenzamide was similar between men (N=40) and women (N=28).
Pharmacokinetics appeared to be similar for Caucasians (N=53) and African Americans (N=12).
The clearance of trimethobenzamide is not known in patients with renal impairment. However, it may be advisable to consider reduction in the dosing of trimethobenzamide in patients with renal impairment considering that a substantial amount of excretion and elimination of trimethobenzamide occurs via the kidney. (See PRECAUTIONS: General and DOSAGE AND ADMINISTRATION ).
Indications and usage
Trimethobenzamide hydrochloride capsules, USP are indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.
Use of any dosage form in patients with known hypersensitivity to trimethobenzamide is contraindicated.
Caution should be exercised when administering trimethobenzamide hydrochloride capsules, USP to children for the treatment of vomiting. Antiemetics are not recommended for treatment of uncomplicated vomiting in children and their use should be limited to prolonged vomiting of known etiology. There are two principal reasons for caution:
- The extrapyramidal symptoms which can occur secondary to trimethobenzamide hydrochloride capsules, USP may be confused with the central nervous system signs of an undiagnosed primary disease responsible for the vomiting, e.g., Reye's syndrome or other encephalopathy.
- It has been suspected that drugs with hepatotoxic potential, such as trimethobenzamide hydrochloride capsules, USP, may unfavorably alter the course of Reye's syndrome. Such drugs should therefore be avoided in children whose signs and symptoms (vomiting) could represent Reye's syndrome.
Trimethobenzamide hydrochloride capsules, USP may produce drowsiness. Patients should not operate motor vehicles or other dangerous machinery until their individual responses have been determined.
Usage in Pregnancy:Trimethobenzamide hydrochloride was studied in reproduction experiments in rats and rabbits and no teratogenicity was suggested. The only effects observed were an increased percentage of embryonic resorptions or stillborn pups in rats administered 20 mg and 100 mg/kg and increased resorptions in rabbits receiving 100 mg/kg. In each study these adverse effects were attributed to one or two dams. The relevance to humans is not known. Since there is no adequate experience in pregnant or lactating women who have received this drug, safety in pregnancy or in nursing mothers has not been established.
Spl unclassified section
Usage with Alcohol:Concomitant use of alcohol with trimethobenzamide hydrochloride capsules, USP may result in an adverse drug interaction.
During the course of acute febrile illness, encephalitides, gastroenteritis, dehydration and electrolyte imbalance, especially in children and the elderly or debilitated, CNS reactions such as opisthotonos, convulsions, coma and extrapyramidal symptoms have been reported with and without use of trimethobenzamide hydrochloride capsules, USP or other antiemetic agents. In such disorders caution should be exercised in administering trimethobenzamide hydrochloride capsules, USP, particularly to patients who have recently received other CNS-acting agents (phenothiazines, barbiturates, belladonna derivatives). Primary emphasis should be directed toward the restoration of body fluids and electrolyte balance, the relief of fever and relief of the causative disease process. Overhydration should be avoided since it may result in cerebral edema.
The antiemetic effects of trimethobenzamide hydrochloride capsules, USP may render diagnosis more difficult in such conditions as appendicitis and obscure signs of toxicity due to overdosage of other drugs.
Clinical studies of trimethobenzamide hydrochloride did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Although there are studies reported in the literature that included elderly patients >65 years old with younger patients, it is not known if there are differences in efficacy or safety parameters for elderly and non-elderly patients treated with trimethobenzamide. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION ).
There have been reports of hypersensitivity reactions and Parkinson-like symptoms. There have been instances of hypotension reported following parenteral administration to surgical patients. There have been reports of blood dyscrasias, blurring of vision, coma, convulsions, depression of mood, diarrhea, disorientation, dizziness, drowsiness, headache, jaundice, muscle cramps and opisthotonos. If these occur, the administration of the drug should be discontinued. Allergic-type skin reactions have been observed; therefore, the drug should be discontinued at the first sign of sensitization. While these symptoms will usually disappear spontaneously, symptomatic treatment may be indicated in some cases.
Dosage and administration
Dosage should be adjusted according to the indication for therapy, severity of symptoms and the response of the patient.
Dose adjustment such as reducing the total dose administered at each dosing or increasing the dosing interval should be considered in elderly patients with renal impairment (creatinine clearance 70 mL/min/1.73m 2). Final dose adjustment should be based upon integration of clinical efficacy and safety considerations. (See CLINICAL PHARMACOLOGY and PRECAUTIONS ).
Patients with renal impairment
In subjects with renal impairment (creatinine clearance 70 mL/min/1.73m 2), dose adjustment such as reducing the total dose administered at each dosing or increasing the dosing interval should be considered. (See CLINICAL PHARMACOLOGY and PRECAUTIONS ).
CAPSULES, 300 mg
Usual Adult Dosage
One 300 mg capsule t.i.d. or q.i.d.
NDC 69189-0376-1single dose pack with 1 capsule as repackagedby Avera McKennan Hospital
|Bottles of 30||NDC 53489-376-07|
|Bottles of 60||NDC 53489-376-06|
|Bottles of 100||NDC 53489-376-01|
|Bottles of 250||NDC 53489-376-03|
|Bottles of 500||NDC 53489-376-05|
|Bottles of 1000||NDC 53489-376-10|
Storage and handling section
Store at 20 to 25C (68 to 77F).
[See USP Controlled Room Temperature]
DISPENSE IN TIGHT, LIGHT-RESISTANT CONTAINER.
Spl unclassified section
Distributed by: Sun Pharmaceutical Industries, Inc.
Cranbury, NJ 08512
Rev 05, December 2014
Ingredients and appearance - Product information
Trimethobenzamide hydrochloride capsule- Trimethobenzamide hydrochloride
|Product Type||HUMAN PRESCRIPTION DRUG LABEL||Item Code (Source)||NDC: 69189-0376|
|Route of Administration||Oral|
|Trimethobenzamide hydrochloride ( UNII: WDQ5P1SX7Q)( Trimethobenzamide - UNII: W2X096QY97 )||300 mgin 1|
|Ferric oxide red||( UNII: 1K09F3G675)|
|Gelatin||( UNII: 2G86QN327L)|
|Magnesium stearate||( UNII: 70097M6I30)|
|Cellulose, microcrystalline||( UNII: OP1R32D61U)|
|Titanium dioxide||( UNII: 15FIX9V2JP)|
|D&c yellow no. 10||( UNII: 35SW5USQ3G)|
|Aluminum oxide||( UNII: LMI26O6933)|
|Fd&c blue no. 1||( UNII: H3R47K3TBD)|
|Fd&c blue no. 2||( UNII: L06K8R7DQK)|
|Fd&c red no. 40||( UNII: WZB9127XOA)|
|Ferrosoferric oxide||( UNII: XM0M87F357)|
|Propylene glycol||( UNII: 6DC9Q167V3)|
|Shellac||( UNII: 46N107B71O)|
|Sodium starch glycolate type a potato||( UNII: 5856J3G2A2)|
|Color||orange (Swedish Orange Opaque)||Score||1|
|#||Item Code||Package Description||Marketing Start Date|
|1||NDC: 69189-0376-1||1 DOSE PACK||2015/07/16|
|Marketing Category||Application Number or Monograph Citation||Territorial Authority||Marketing Start Date|
Labeler - Avera McKennan Hospital( 068647668)
|Avera McKennan Hospital||068647668||relabel( 69189-0376), repack( 69189-0376)|